The Biotechnology Value Fund was to announce today that it is opposed to the proposed merger between Arris and Sequana. The fund holds a 5 percent stake in ARRS, according to fund manager Mark Lampert.

Lampert on Sunday told BioCentury that he has spoken to other ARRS shareholders who oppose the merger, which they see as a combination of unequals, yet which would give SQNA shareholders an equal stake in the combined company (see BioCentury Extra, Nov. 4).